HD-OPM Archive
Topics › Weight, visceral & liver fat

Curcumin 1,000 mg/day for 8 weeks improved liver fat in NAFLD RCT (n=87)

Louis Nervegna · Jun 24, 2026 · ♥ 12 reactions · 12 comments · original Facebook post
Weight, visceral & liver fatSupplements & vitamins
AI summary & key facts

Louis reshares his summary of a randomized trial of phytosomal curcumin in 87 patients with NAFLD. After 8 weeks it improved ultrasound steatosis, BMI, waist circumference and liver enzymes versus placebo, with good tolerability.

(no text — see the shared post below)

Research cited

8 weeks of Curcumin Supplementation Decreases Liver Fat
This randomised controlled trial involved 87 patients with NAFLD (grades 1-3, diagnosed by liver ultrasound).

Patients were randomised to take curcumin (1000 mg/day in two divided doses) or a placebo for 8 weeks.

Curcumin was provided as a phytosomal formulation that contained a complex of curcumin and soy phosphatidylcholine (Meriva, provided by Indena SpA). Participants in both groups were also given dietary and lifestyle recommendations.

After 8 weeks, curcumin supplementation, but not the placebo, produced statistically significant reductions in body mass index (BMI) and waist circumference (p<.001).

Liver ultrasound findings improved in 75% of subjects in the curcumin group and only 4.7% of subjects in the placebo group.

Improvements on ultrasound were statistically significant in the curcumin group when compared with the placebo (p<.001).

Furthermore, 34.1% of patients in the treatment group saw their liver fat resolve completely, reaching Grade 0. All patients in the treatment group with high-grade (Grade 3) steatosis experienced a reduction in severity.

The effect of curcumin in reducing liver fat remained significant after adjusting for numerous confounding factors. In addition, serum levels of AST and ALT were reduced after 8 weeks of curcumin supplementation but increased in the placebo group. Curcumin was well tolerated, with no reports of serious adverse events.

This study shows that 8 weeks of curcumin supplementation improves sonographic findings and hepatic transaminase levels in patients with NAFLD.

Quoted:

“Supplementation with curcumin was associated with a reduction in body mass index (-0.99±1.25 vs. - 0.15±1.31 in the curcumin and placebo groups, respectively; p=0.003) and waist circumference (-1.74±2.58 vs. -0.23±3.49 in the curcumin and placebo groups, respectively; p=0.024). Ultrasonographic findings were improved in 75.0% of subjects in the curcumin group, while the rate of improvement in the control group was 4.7% (p<0.001). Serum levels of aspartate aminotransferase and alanine aminotransferase were reduced by the end of trial in the curcumin group (p<0.001) but elevated in the control group (p<0.001). Curcumin was safe and well tolerated during the course of trial.”

Paper · Drug Res (Stuttg) · 2017Efficacy and Safety of Phytosomal Curcumin in Non-Alcoholic Fatty Liver Disease: A Randomized Controlled Trial.Non-alcoholic fatty liver disease (NAFLD) is a common liver disease characterized by excess lipid deposition in the hepatic tissue and subsequent oxidative and inflammatory damage. Curcumin is a dietary polyphenol with lipid-modifying, antioxidant and anti-inflammatory properties. This study aimed to evaluate the efficacy and safety of supplementation with phytosomal curcumin in subjects with NAFLD.Patients…pubmed.ncbi.nlm.nih.gov

#curcuminHD #liverfatHD #fattyliverHD #liverfatsummaryHD

← newer: A CAC score of zero does not rule out atherosclerosis, especolder: Curcumin has the strongest natural-product evidence for lowe →